Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 05 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has received final approval from the USFDA for Dasatinib Tablets in various strengths. Dasatinib is used for treating specific types of leukemia in adults. The tablets will be manufactured at Zydus Lifesciences' facility in Ahmedabad.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 05, 2025, titled "Zydus receives final approval from USFDA for Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases